Fresenius Kabi is expanding its growing biopharma portfolio through a new licensing agreement with Polpharma Biologics S.A. Fresenius Kabi will commercialize Polpharma Biologics’ vedolizumab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback